News from SGC

Posted on Tuesday 25th of February 2014
The Structural Genomics Consortium (SGC) and DiscoveRx Corporation announced the publication of findings demonstrating that several clinical kinase inhibitors also potently inhibit diverse bromodomain epigenetic reader proteins. This study titled “Dual kinase-bromodomain inhibitors for rationally designed polypharmacology”, which appears on-line today in Nature Chemical Biology , suggests compelling new multi-targeting approaches for cancer therapy.
Posted on Thursday 19th of December 2013
Bayer Inc. is pleased to announce that Bayer HealthCare has joined the SGC, a not-for-profit, public-private partnership with active research facilities at the Universities of Toronto and Oxford, UK.
Posted on Tuesday 26th of November 2013
The Open Access nature of SGC work is discussed in this article on
Posted on Sunday 27th of October 2013
The Structural Genomics Consortium (SGC) announced today that Janssen Pharmaceuticals NV has joined its group to partner in the investigation of epigenetics-based drug research, a new and burgeoning field in the development of future medicines.
Posted on Sunday 27th of October 2013
The SGC's Prof. Chas Bountra interviewed for the University of Oxford website. [article].
Posted on Friday 9th of August 2013
Today we learned the sad news that Tony Pawson, a former member of the SGC Scientific Committee, and a friend and colleague of many SGC scientists, died this week. He was a fantastic person, scientist and collaborator.
Posted on Tuesday 16th of July 2013
The Structural Genomics Consortium (SGC) recently launched a new scientific public-private partnership in tuberculosis and malaria drug discovery: the Structure-guided Drug Discovery Coalition, SDDC.
Posted on Tuesday 7th of May 2013
Boehringer Ingelheim announced that it has joined the Structural Genomics Consortium (SGC) for further research into incurable diseases.


Subscribe to News from SGC
glqxz9283 sfy39587stf02 mnesdcuix8